TENNESSEE GENERAL ASSEMBLY FISCAL REVIEW COMMITTEE



FISCAL NOTE

SB 3625 - HB 3921

March 4, 2010

SUMMARY OF BILL: Authorizes the Commissioner of Health to charge fees to insurers who do not reimburse patients for the purchase of approved drugs for off label use.

ESTIMATED FISCAL IMPACT:

Increase State Revenue - Not Significant Increase State Expenditures - Not Significant

Assumptions:

- According to the Department of Health, rulemaking will be required to establish the fee structure and disciplinary guidelines. Any cost can be accommodated within existing resources without an increased appropriation or reduced reversion.
- It is estimated that any increase in revenue as a result of the reasonable fees charged to an insurance company that fails to comply will not be significant.

CERTIFICATION:

The information contained herein is true and correct to the best of my knowledge.

James W. White, Executive Director

/kml